Table 2.
Factors associated with event-free and overall survival (n = 111).
| Outcome, Variable | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Event-free survival | ||||
| Pathologic primary tumor size, cm | 1.15 (1.03–1.28) | 0.013 | 1.15 (1.03–1.29) | 0.014 |
| Lymphovascular invasion | 1.85 (1.16–2.96) | 0.010 | 1.73 (1.06–2.84) | 0.029 |
| Overall survival | ||||
| Receipt of neoadjuvant therapy | 0.52 (0.30–0.89) | 0.018 | 0.43 (0.24–0.77) | 0.004 |
| Pathologic primary tumor size, cm | 1.21 (1.06–1.38) | 0.004 | 1.18 (1.02–1.35) | 0.023 |
| Pathologic N1 or N2 disease (vs. N0) | 2.05 (1.18–3.56) | 0.010 | 1.83 (1.05–3.20) | 0.033 |
| Visceral pleural invasion | 2.45 (1.42–4.21) | 0.001 | 1.93 (1.10–3.40) | 0.022 |
CI, confidence interval; HR, hazard ratio. The full univariable analysis for event-free survival (EFS) and overall survival (OS) is included in Supplementary Tables S1 and S2, respectively.